Regional, Synpatic, Cellular Modulation of Abeta Metabolism
Project Number5P01NS074969-02
Contact PI/Project LeaderHOLTZMAN, DAVID M.
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia. There is compelling data that the amyloid- beta (Abeta) peptide plays a key early role in initiating disease pathogenesis. The progressive buildup of toxic forms of Abeta in the brain appears to ultimately lead to downstream events culminating in dementia. Since the concentration of soluble Abeta peptide is directly related to the probability that it will aggregate, determining what normally regulates Abeta levels in the brain will likely provide critical insights ino factors that initiate the AD pathological cascade. The investigators on this PPG proposal have found that synaptic activity is dynamically coupled with the release of the Abeta peptide in the extracellular space of the brain. Our labs have utilized mouse models of AD to discover some of the cellular mechanisms that link synaptic transmission and dynamic changes in Abeta levels in awake, behaving mice with confirmation in human studies. Abeta is dynamically regulated by the sleep-wake cycle and this regulation appears important in determining Abeta deposition later in life. The regulation of Abeta by the sleep-wake cycle may be tied to synaptic activity as brain interstitial fluid (ISF) levels of Abeta are directly coupled with synaptic activity both pre- and post-synapticall. A molecule likely involved in this coupling is LRP1, since APP endocytosis is required for a large component of Abeta generation and LRP1 influences APP endocytosis and Abeta generation. Our hypothesis is that synaptic activity influences both Abeta production and clearance in the brain and that over time this activity influences whether, where, and when Abeta aggregates into toxic species in the brain. In addition, we hypothesize that synaptic activity-mediated Abeta generation and release 1) is influenced by the sleep/wake cycle and molecules that regulate that cycle; 2) occurs in part via post-synaptic stimulation of NMDA receptors via ERK signaling; and 3) is influenced by the LDL-receptor related protein-1 (LRP1) via its interactions with APP. We will combine unique techniques including in vivo protein microdialysis, 13C-labeled amino acid pulse chase labeling combined with mass spectrometry, and focal viral-mediated gene delivery with approaches that assess systems level network function, synaptic and molecular signaling, and cell biology.
Public Health Relevance Statement
Alzheimer's disease is the most common cause of dementia and a major public health problem. The number of cases will likely double in the next 20 years without an effective treatment. Understanding the effects of brain networks, the sleep-wake cycle, and the synaptic, cellular and molecular mechanisms underlying Abeta regulation will provide novel insights into AD pathogenesis and potentially new treatment ideas.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
068552207
UEI
L6NFUM28LQM5
Project Start Date
15-May-2012
Project End Date
30-April-2017
Budget Start Date
01-May-2013
Budget End Date
30-April-2014
Project Funding Information for 2013
Total Funding
$1,106,922
Direct Costs
$809,954
Indirect Costs
$296,968
Year
Funding IC
FY Total Cost by IC
2013
National Institute of Neurological Disorders and Stroke
$1,106,922
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01NS074969-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01NS074969-02
Patents
No Patents information available for 5P01NS074969-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01NS074969-02
Clinical Studies
No Clinical Studies information available for 5P01NS074969-02
News and More
Related News Releases
No news release information available for 5P01NS074969-02
History
No Historical information available for 5P01NS074969-02
Similar Projects
No Similar Projects information available for 5P01NS074969-02